MTND4P16

Across TCGA pan-cancer cohorts, MTND4P16 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated MTND4P16 data layer.

The strongest signal is observed in thyroid carcinoma (THCA), where higher MTND4P16 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTND4P16 expression acts as an unfavorable survival marker, although some lineages such as KIRP and OV show a favorable association.

THCA, UCS, and READ are the cancer types where MTND4P16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Tertile	IV	0.514	0.937	<.001	39	view →
UCS	OS	Tertile	III,IV	0.135	0.590	.048	36	view →
READ	DFS	Tertile	IV	0.082	0.619	.001	36	view →
KIRP	OS	Tertile	III,IV	1.000	0.384	.015	33	view →
LIHC	DFS	Tertile	III,IV	0.088	0.337	.002	27	view →
OV	OS	Median	All	0.378	0.294	.014	24	view →
LUSC	OS	Tertile	III,IV	0.054	0.768	<.001	18	view →
PRAD	OS	Tertile	All	0.940	0.993	<.001	12	view →
ACC	DFS	Tertile	IV	0.068	0.402	.031	9	view →
PCPG	OS	Tertile	All	0.828	0.963	<.001	9	view →
BRCA	DFS	Tertile	III,IV	0.962	0.863	.044	6	view →
STAD	DFS	Median	IV	0.308	0.624	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

MTND4P16–THCA (DFS)

Open the THCA breakdown →